Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07146750 · ClinicalTrials.gov registry record · Phase 1
A Bioequivalence Study of Amlitelimab Delivered by 2 Different Devices in Healthy Adult Participants
A Phase 1 study of Healthy Volunteers, sponsored by Sanofi.
- Active
- Registry status
- Phase 1
- Development phase
- 212
- Enrollment target
- 1
- Study location
NCT07146750 is a Phase 1 study of Healthy Volunteers that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 212 participants, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07146750, a Phase 1 study of Healthy Volunteers, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 212 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, open-label, randomized, single-dose, parallel, Phase 1, 4-arm study designed to determine the bioequivalence and investigate the safety and tolerability profiles of subcutaneous amlitelimab delivered by 2 different devices at 2 different total doses in healthy adult participants.
Conditions Studied
Interventions
- COMBINATION_PRODUCT SAR445229
Study Locations (1)
Florida
- Clinical Pharmacology of Miami- Site Number : 8400001 - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2025-08-25 |
| Est. Completion | 2026-04-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07146750
The ClinicalTrials.gov registry entry for NCT07146750 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (56% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which SAR445229 is the first listed.
NCT07146750 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07146750 about?
NCT07146750 is a clinical study titled "A Bioequivalence Study of Amlitelimab Delivered by 2 Different Devices in Healthy Adult Participants". This is a single-center, open-label, randomized, single-dose, parallel, Phase 1, 4-arm study designed to determine the bioequivalence and investigate the safety and tolerability profiles of subcutaneous amlitelimab delivered by 2 different devices at 2 different total doses in healthy adult particip...
What is the current status of trial NCT07146750?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 212 participants. The study started on 2025-08-25. Estimated completion is 2026-04-08.
What conditions does trial NCT07146750 study?
This clinical trial studies the following conditions: Healthy Volunteers.
What interventions are being tested in trial NCT07146750?
The interventions under investigation include: SAR445229 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07146750?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07146750 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
RECRUITING · Phase 1
-
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
RECRUITING · Phase 1
-
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.
RECRUITING · Phase 1
-
Classroom Break, Cognition, and Fitness in Elementary School Children
RECRUITING · Phase 1
-
A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.